BGLC

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.30
Percentage change 10.83	%

Peers: ILMN GH EXAS QGEN MYGN CRSP FATE FLGT CGEN EDIT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.18	Insider Own	34.65%	Shs Outstand	1.80M	Perf Week	12.04%
Market Cap	5.52M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.17M	Perf Month	-20.88%
Enterprise Value	2.12M	PEG	-	EPS next Q	-	Inst Own	0.88%	Short Float	1.36%	Perf Quarter	22.75%
Income	-2.12M	P/S	0.60	EPS this Y	-	Inst Trans	-10.79%	Short Ratio	0.03	Perf Half Y	26.34%
Sales	9.27M	P/B	0.71	EPS next Y	-	ROA	-20.52%	Short Interest	0.02M	Perf YTD	9.76%
Book/sh	4.33	P/C	1.53	EPS next 5Y	-	ROE	-24.75%	52W High	8.40 -63.45%	Perf Year	-37.35%
Cash/sh	2.00	P/FCF	-	EPS past 3/5Y	- -21.27%	ROIC	-26.74%	52W Low	2.01 52.98%	Perf 3Y	-98.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-10.72% 137.09%	Gross Margin	12.78%	Volatility	10.08% 10.88%	Perf 5Y	-
Dividend TTM	-	EV/Sales	0.23	EPS Y/Y TTM	27.28%	Oper. Margin	-24.74%	ATR (14)	0.32	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.44	Sales Y/Y TTM	-5.21%	Profit Margin	-22.86%	RSI (14)	53.04	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	4.19	EPS Q/Q	-490.97%	SMA20	2.60%	Beta	1.80	Target Price	-
Payout	-	Debt/Eq	0.03	Sales Q/Q	-10.28%	SMA50	3.58%	Rel Volume	0.21	Prev Close	2.77
Employees	30	LT Debt/Eq	0.02	Earnings	-	SMA200	-6.88%	Avg Volume	621.79K	Price	3.07
IPO	Sep 16, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	128,999	Change	10.83%

Apr-30-25 11:25AM	BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness (GlobeNewswire)
Apr-15-25 11:00AM	BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory (GlobeNewswire) +14.22%
Mar-08-25 11:10AM	Bionexus Gene Lab enters partnership with ML Tech (TipRanks)
Mar-07-25 11:00AM	BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy (GlobeNewswire) +6.96%
Mar-05-25 11:00AM	BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper (GlobeNewswire)
11:31AM	Loading…
Sep-25-24 11:31AM	BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd. (GlobeNewswire)
Sep-13-24 12:05PM	BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd. (GlobeNewswire)
Sep-12-24 01:23PM	BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions (GlobeNewswire) +8.36%
Sep-11-24 11:05AM	BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production (GlobeNewswire)
Aug-27-24 11:35AM	BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd (GlobeNewswire)
Aug-26-24 12:15PM	BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd (GlobeNewswire)
Jul-15-24 07:35AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Apr-19-24 08:58AM	Why Is BioNexus Gene Lab (BGLC) Stock Down 27% Today? (InvestorPlace) -29.32%
Apr-18-24 02:52PM	BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare (GlobeNewswire) +34.00%
Jul-24-23 11:30AM	BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market (GlobeNewswire) -10.08%
01:29PM	Loading…
Jul-20-23 01:29PM	BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market (GlobeNewswire) -55.40%

BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded by Liew Choong-Chin on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BioNexus Gene Lab Corp

Upgrade your FINVIZ experience